Substituted Fused Pyrimidine Compounds for Adenosine Receptor Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases mediated by adenosine receptor activity, such as asthma, chronic obstructive pulmonary disease, and inflammatory disorders, lack effective antagonists that can selectively target adenosine receptors, particularly A2B and A1 subtypes, to provide comprehensive therapeutic benefits.
Innovation Solution
Development of novel substituted fused pyrimidine compounds that act as potent antagonists of the A2B and non-selective antagonists of adenosine receptors, capable of treating conditions by modulating adenosine receptor activity, including asthma, COPD, and inflammatory diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for adenosine receptor-mediated diseases are used, then existing therapeutic options are available, but they lack effective antagonists that can selectively target adenosine receptors (particularly A2B and A1 subtypes)
Solution Approach 1:
The patent segments the adenosine receptor targeting by developing compounds with selective affinity for specific subtypes (A2B and A1 receptors). The substituted fused pyrimidine structure allows differential binding to various adenosine receptor subtypes, enabling selective pharmacological modulation of each subtype to address different disease mechanisms.
Solution Approach 2:
The patent introduces specific substituent groups at defined positions on the fused pyrimidine core structure to optimize local interactions with specific adenosine receptor subtypes. The R1, R2, R3, R4, and substituent groups are strategically positioned to create local chemical environments that enhance selectivity for A2B or A1 receptors while maintaining overall compound stability.
2Reliability
If novel substituted fused pyrimidine compounds are developed to selectively target adenosine receptors, then comprehensive therapeutic benefits can be achieved, but the complexity of drug development increases
Solution Approach 1:
The fused pyrimidine core structure serves as a universal scaffold that can accommodate multiple substituent variations while maintaining binding affinity for adenosine receptors. This multi-functional platform allows a single core structure to generate multiple analogs with different selectivity profiles (A2B-selective, A1-selective, or non-selective), reducing the need to develop entirely separate molecular frameworks for each therapeutic indication.
Solution Approach 2:
The patent systematically varies chemical parameters (substituent types, positions, and configurations) on the fused pyrimidine core to optimize receptor binding characteristics. By changing parameters such as the nature of R1, R2, R3, R4 groups and their configurations, the compound profile can be tuned to achieve desired selectivity and potency without fundamentally altering the core structure, thereby managing development complexity.
Data Source
AI summary
The present invention provides substituted fused pyrimidine compounds of formula (I), their tautomers, polymorphs, stereoisomers, prodrugs, solvates, pharmaceutically acceptable salts, pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by adenosine receptor (AR) activity. The present invention also provides processes for preparation of compounds of formula (I).